CLINICAL_TRIALS
trial_result
· 2017-01-30
Clinical Trial Update: Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma [Phase 2]
Summary
A Phase 2 placebo-controlled trial of VS-6063 (defactinib) in malignant pleural mesothelioma was terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Verastem, Inc. | Conditions: Malignant Pleural Mesothelioma | Phase 2 | Status: TERMINATED